Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Hospital Universitari Vall d'Hebron Research Institute
Summary
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Description
It is a 2-year, multicenter observational study. Patients who meet reimbursement criteria according to local regulations and willing to participate in the study will be included. Monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) will be started and baseline assessment will be conducted. There will be visits every 6 months to assess effectiveness, side-effects, PROMs, and elegibility to continue with the study drug. The observation of patients will last 2 years.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Migraine diagnosis according to ICHD-III. * Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations. * Signature of informed consent. Exclusion Criteria: * Presence of headache different from migraine. * Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.
Interventions
- DrugCGRP antibody or gepant
Patients will start anti-CGRP or its receptor antibody or gepants
Locations (26)
- University of Miami, Miller School of MedicineMiami, Florida
- FLENIBuenos Aires
- Pontificia Universidad Católica de ChileSantiago
- NeuromedicaMedellín
- Special Hospital for Orthopedics and Rehabilitation "Martin Horvat" Rovinj-RovignoRovinj
- Charité Universitätsmedizin BerlinBerlin